Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Withdrawn 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 17Rituximab 12Prednisone 7Peripheral Blood Stem Cell Transplantation 7Filgrastim 7sargramostim 6Vincristine 6fludarabine phosphate 5Radiotherapy 5Doxorubicin 5Cytarabine 5Cisplatin 5ibritumomab tiuxetan 4Methylprednisolone 4Melphalan 4Etoposide 4Dexamethasone 4Cyclosporine 4epratuzumab 3Sensitivity and Specificity 3Polymerase Chain Reaction 3Mycophenolic Acid 3Indium 3Chlorambucil 3Busulfan 3Bendamustine Hydrochloride 3Antilymphocyte Serum 3Antigens, CD19 3obinutuzumab 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Follicular × duvelisib × Clear all
NCT04707079 2021-01-13

A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
24 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡